.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Cipla
Chinese Patent Office
Boehringer Ingelheim
McKinsey
Healthtrust
Citi
Fish and Richardson
Accenture
US Department of Justice

Generated: December 14, 2017

DrugPatentWatch Database Preview

Clindamycin phosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for clindamycin phosphate and what is the scope of clindamycin phosphate patent protection?

Clindamycin phosphate
is the generic ingredient in seventeen branded drugs marketed by Perrigo Uk Finco, Mylan Pharms Inc, Pharmacia And Upjohn, Fougera Pharms, Perrigo Pharma Intl, Precision Dermat, Abraxis Pharm, Alvogen Inc, Bedford, Bristol Myers Squibb, Fresenius Kabi Usa, Igi Labs Inc, Loch, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Solopak, Teva Parenteral, Watson Labs, West-ward Pharms Int, Akorn Inc, Baxter Hlthcare Corp, Sandoz Inc, Abbvie, Baxter Hlthcare, Paddock Llc, Boca Pharma Llc, Fougera Pharms Inc, G And W Labs Inc, Novast Labs Ltd, Perrigo New York, Taro Pharm Inds, Teligent Pharma Inc, Vintage Pharms, Wockhardt, Akorn, Perrigo Co, Actavis Mid Atlantic, Aqua Pharms Llc, and Medicis, and is included in sixty-nine NDAs. There are six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Clindamycin phosphate has one hundred and twenty-four patent family members in thirty-six countries and nine supplementary protection certificates in eight countries.

There are fifty-three drug master file entries for clindamycin phosphate. Thirty-four suppliers are listed for this compound.

Pharmacology for clindamycin phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Pharmacia And UpjohnCLEOCIN PHOSPHATEclindamycin phosphateINJECTABLE;INJECTION061839-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Aqua Pharms LlcVELTINclindamycin phosphate; tretinoinGEL;TOPICAL050803-001Jul 16, 2010BXRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
MedicisZIANAclindamycin phosphate; tretinoinGEL;TOPICAL050802-001Nov 7, 2006ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pharmacia And UpjohnCLEOCIN Tclindamycin phosphateSOLUTION;TOPICAL050537-001Approved Prior to Jan 1, 1982ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Pharmacia And UpjohnCLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINERclindamycin phosphateINJECTABLE;INJECTION050639-003Apr 10, 1991APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis PharmCLINDAMYCIN PHOSPHATEclindamycin phosphateINJECTABLE;INJECTION062747-001Jun 3, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Teva ParenteralCLINDAMYCIN PHOSPHATEclindamycin phosphateINJECTABLE;INJECTION063041-001Dec 29, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Perrigo New YorkCLINDAMYCIN PHOSPHATEclindamycin phosphateSOLUTION;TOPICAL064050-001Nov 30, 1995ATRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sandoz IncCLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINERclindamycin phosphateINJECTABLE;INJECTION201692-003May 31, 2012APRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Pharmacia And UpjohnCLEOCIN PHOSPHATEclindamycin phosphateINJECTABLE;INJECTION062803-001Oct 16, 1987APRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: clindamycin phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma IntlCLINDESSEclindamycin phosphateCREAM;VAGINAL050793-001Nov 30, 2004► Subscribe► Subscribe
Perrigo Pharma IntlCLINDESSEclindamycin phosphateCREAM;VAGINAL050793-001Nov 30, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: clindamycin phosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,416,778 Pharmaceutical preparations and methods for their regional administration► Subscribe
7,749,488Pharmaceutical foam► Subscribe
6,652,874 Pharmaceutical preparations and methods for their regional administration► Subscribe
6,517,847 Topical gel delivery system► Subscribe
9,486,394Pharmaceutical foam► Subscribe
8,586,008Pharmaceutical foam► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: clindamycin phosphate

Country Document Number Estimated Expiration
European Patent Office2316424► Subscribe
Israel169761► Subscribe
Australia2003218233► Subscribe
Denmark1200065► Subscribe
World Intellectual Property Organization (WIPO)9832422► Subscribe
Japan2011225585► Subscribe
Argentina030093► Subscribe
MexicoPA05007722► Subscribe
Morocco26749► Subscribe
Portugal2052714► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CLINDAMYCIN PHOSPHATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90049-3Sweden► SubscribePRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
4Finland► Subscribe
2013025Lithuania► SubscribePRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Moodys
Colorcon
Fuji
US Army
Cipla
Novartis
Healthtrust
Dow
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot